These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16884574)

  • 1. Management of medicines information for patient safety.
    Pappa D; Telonis P; Stergioulas LK
    J Telemed Telecare; 2006; 12 Suppl 1():34-6. PubMed ID: 16884574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do themes in consumer medicines information literature reviews reflect those important to stakeholders?
    Nicolson DJ; Knapp P; Raynor DK; Grime J; Pollock K
    Patient Educ Couns; 2006 Dec; 64(1-3):112-8. PubMed ID: 16431071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Communication and transparency concerning risk-benefit analysis in public health: the example of medication].
    Lehner JP; Meyer F; Juillet Y
    Therapie; 2001; 56(4):335-9. PubMed ID: 11677849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural health product labels: is more information always better?
    Boon HS; Kachan N
    Patient Educ Couns; 2007 Oct; 68(2):193-9. PubMed ID: 17693048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evaluation of an integrated pharmaceutical education system.
    Liu CT; Yeh YT; Chiang IJ; Chen HY; Lee TI; Chiu WT
    Int J Med Inform; 2004 May; 73(4):383-9. PubMed ID: 15135757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient information leaflets--helpful guidance or a source of confusion?
    Bjerrum L; Foged A
    Pharmacoepidemiol Drug Saf; 2003; 12(1):55-9. PubMed ID: 12616848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What can we learn about patient safety from information sources within an acute hospital: a step on the ladder of integrated risk management?
    Hogan H; Olsen S; Scobie S; Chapman E; Sachs R; McKee M; Vincent C; Thomson R
    Qual Saf Health Care; 2008 Jun; 17(3):209-15. PubMed ID: 18519628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keeping up with drug safety information.
    Meadows M
    FDA Consum; 2006; 40(3):38-9. PubMed ID: 16906667
    [No Abstract]   [Full Text] [Related]  

  • 9. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions in childhood: a review of prospective studies and safety alerts.
    Clavenna A; Bonati M
    Arch Dis Child; 2009 Sep; 94(9):724-8. PubMed ID: 19531524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active drug safety surveillance: a tool to improve public health.
    Platt R; Madre L; Reynolds R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1175-82. PubMed ID: 18823068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An assessment of direct-to-consumer advertising of prescription drugs.
    Calfee JE
    Clin Pharmacol Ther; 2007 Oct; 82(4):357-60. PubMed ID: 17851572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety information project on drug, food and chemicals. Division of Safety Information on Drug, Food and Chemicals. National Institute of Health Sciences].
    Morikawa K; Yamamoto M; Nakano T; Kasuga F; Yamamoto M
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2003; (121):1-11. PubMed ID: 14740398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keeping up with drug use and safety.
    Long CO
    Home Healthc Nurse; 2004 Aug; 22(8):530-1. PubMed ID: 15314556
    [No Abstract]   [Full Text] [Related]  

  • 16. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from cisapride.
    CMAJ; 2001 May; 164(9):1269, 1271. PubMed ID: 11341130
    [No Abstract]   [Full Text] [Related]  

  • 18. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Children and parents need better information on medicines.
    Shaw JM
    BMJ; 2004 Feb; 328(7438):525. PubMed ID: 14988212
    [No Abstract]   [Full Text] [Related]  

  • 20. Short communication: pattern of adverse drug reaction related queries received by the drug information centre of a tertiary care teaching hospital.
    Jimmy B; Jose J; Rao PG
    Pak J Pharm Sci; 2007 Oct; 20(4):333-9. PubMed ID: 17604259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.